Mesothelioma Clinical Trial Matches Treatment to Genetic Profiles
This study met its primary endpoint, showing promising clinical activity of abemaciclib in patients with p16ink4A-negative mesothelioma who were previously treated with chemotherapy,” the authors concluded. “[This therapy] warrants further investigation in a randomized study as targeted stratified therapy.”
Some patients may have genes that allow a particular response to a drug, such as abemaciclib, but there is still potential to find targets beneficial to other patients.
The researchers are interested in adding additional therapy options for patients as the clinical trial continues. Depending on their genetic profile, patients may also receive rucaparib, an FDA-approved drug for certain types of ovarian cancer, or a combination of immunotherapy drugs.
Contingent on the trial’s success in the future, it may expand to more mesothelioma cancer treatment centers across the U.K. Identifying additional biomarkers that can treat a broader range of patients is key to developing treatment plans tailored to each patient’s disease.
The post Mesothelioma Clinical Trial Matches Treatment to Genetic Profiles appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Fran Mannino Source Type: news
More News: Alimta | Asbestosis | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Immunotherapy | Mesothelioma | Ovarian Cancer | Ovaries | Pulmonary Thromboembolism | Study | UK Health